A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults

Trial Profile

A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs MRNA-1653 (Primary)
  • Indications Metapneumovirus infections; Parainfluenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Moderna Therapeutics
  • Most Recent Events

    • 10 Jan 2018 New trial record
    • 08 Jan 2018 According to a Moderna Therapeutics media release, the company began dosing of patients in December 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top